COVID-19, SARS-CoV-2, Immunoassay, MICRO-ELISA kits

SARS-CoV-2 ELISA Assay for the Detection of Neutralizing Antibodies

The COVID-19 pandemic is one of the greatest infectious disease challenges the world has faced in recent history. Presently, few treatment options exist, therefore, the need to evaluate antibodies to fight the SARS-CoV-2 virus is at an all-time high. 

Leinco has developed Trace™, a IgG serology assay using the SARS-CoV-2 receptor-binding domain (RBD) protein as the capture antigen. This ELISA assays is highly sensitive and specific to recent coronavirus exposure. At this time, it is unknown for how long antibodies persist following infection and if the presence of neutralizing antibodies confers protective immunity.